4597.T Stock - Solasia Pharma K.K.
Unlock GoAI Insights for 4597.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $316.00M | $617.00M | $1.09B | $559.00M | $454.00M |
| Gross Profit | $185.00M | $337.00M | $662.00M | $374.00M | $245.00M |
| Gross Margin | 58.5% | 54.6% | 60.6% | 66.9% | 54.0% |
| Operating Income | $-991,000,000 | $-1,139,000,000 | $-2,471,000,000 | $-2,419,000,000 | $-3,315,000,000 |
| Net Income | $-1,941,000,000 | $-1,112,000,000 | $-2,548,000,000 | $-2,477,000,000 | $-4,127,000,000 |
| Net Margin | -614.2% | -180.2% | -233.3% | -443.1% | -909.0% |
| EPS | $-9.77 | $-6.61 | $-16.76 | $-19.03 | $-35.16 |
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4597.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.66 | — | — |
Q2 2025 | May 14, 2025 | — | $-1.34 | — | — |
Q1 2025 | Feb 12, 2025 | — | $-4.91 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-1.23 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-1.57 | — | — |
Q2 2024 | May 15, 2024 | — | $-1.78 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-2.04 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-1.97 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-1.17 | — | — |
Q2 2023 | May 15, 2023 | — | $-1.43 | — | — |
Q1 2023 | Feb 14, 2023 | — | $-2.97 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-4.95 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-4.38 | — | — |
Q2 2022 | May 13, 2022 | — | $-4.61 | — | — |
Q1 2022 | Feb 9, 2022 | — | $-2.75 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-5.46 | — | — |
Q3 2021 | Aug 11, 2021 | — | $-5.68 | — | — |
Q2 2021 | May 12, 2021 | — | $-5.22 | — | — |
Q1 2021 | Feb 10, 2021 | — | $-18.52 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-5.71 | — | — |
Latest News
Frequently Asked Questions about 4597.T
What is 4597.T's current stock price?
What is the analyst price target for 4597.T?
What sector is Solasia Pharma K.K. in?
What is 4597.T's market cap?
Does 4597.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4597.T for comparison